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Background:  Which  surgical  strategy  is the best  one  for  intertrochanteric  fractures  remains  a  controver-
sial  issue.  Dynamic  hip  screw  (DHS)  and  Gamma  nail were  commonly  used  but often  associated  with
some  complications,  such  as  ﬁxation  failure  and  implant-related  fractures.  Meanwhile,  proximal  femoral
nail  anti-rotation  (PFNA)  ﬁxation  has  recently  been  developed  for minimally  invasive  surgery  to  reduce
the  complications  rate.  To facilitate  the  clinical  decision-making,  we  conducted  an  updated  meta-analysis
to discuss  the  optimal  treatment  of intertrochanteric  fractures  aiming  to determine  which  implant  gives
the  lower  rates  of  blood  loss,  complications  (peri-implant  fracture,  ﬁxation  failure,  infection,  throm-
boembolic),  reoperation,  and  mortality,  as well  as  the  minimal  duration  related  to  surgery  (ﬂuoroscopic
exposure,  surgery  and hospital  stay).
Patients  and  methods:  Seven  electronic  databases  were  searched  for randomized  controlled  trials  (includ-
ing OVID,  Springer,  Google  Scholar,  PubMed,  Cochrane  library,  Embase,  and  Web  of  Science).  Fourteen
studies  with  1983  patients  were  included.  The  modiﬁed  Jadad  Scale  was  used  to  assess  the methodologi-
cal  quality  of these  studies.  Risk  of  bias  in  the  included  studies  was  assessed  using  the  Cochrane  Risk  of
Bias  tool.  Comparison  among  the  three  groups  was  based  on  twelve  indicators,  including  operative  time,
ﬂuoroscopy  time,  operative  blood  loss,  length  of  hospital  stays,  wound  infection  or hematoma,  pneumo-
nia,  thromboembolic  complications,  ﬁxation  failure,  operative  fracture  of  femur,  later  fracture  of  femur,
reoperation,  and  mortality.
Results:  (1) PFNA  group  versus  DHS  group:  PFNA  was  associated  with  less  blood  loss  (mean  difference
(MD)  –253.86,  95%  CI –270.25  to  237.47;  P  < 0.00001)  and  lower  rate  of  ﬁxation  failure  (MD  0.20,  95%
CI  0.07  to  0.59; P = 0.004),  but  led  to  more  ﬂuoroscopy  time  (MD 2.11,  95% CI  1.78 to  2.43;  P  < 0.00001).
(2)  PFNA  group  versus  Gamma  nail  group:  PFNA  led to  less  blood  loss  (MD  –55.30,  95%  CI  –60.07  to
–50.53;  P <  0.00001),  shorter  ﬂuoroscopy  time  (MD  –0.50,  95%  CI –0.55 to  –0.45;  P  < 0.00001)  and  length
of  hospital  stay  (MD  –0.20,  95% CI  –0.27 to –0.13;  P  < 0.00001).  (3) DHS  group  versus  Gamma  nail  group:
DHS  was  associated  with  lower  rate  of  operative  fracture  of  femur  (MD 0.31, 95%  CI  0.11  to 0.89; P  =  0.03),
later  fracture  of  femur  (MD 0.16, 95%  CI 0.06  to  0.43;  P =  0.0004),  and  reoperation  (MD  0.49,  95% CI 0.27 to
0.88;  P =  0.02),  but  caused  more  blood  loss  (MD  29.49,  95%  CI  8.27 to  50.70;  P = 0.006).  In contrast,  there
was  no  difference  regarding  operative  time,  infection  hematoma,  pneumonia,  thromboembolic  events,
and mortality.
Discussion:  PFNA  should  be  a priority  choice  for treatment  of intertrochanteric  fractures  with  minimal
rate  of  ﬁxation  failure,  less  blood  loss and  shorter  length  of hospital  stay.  DHS  has  distinct  advantages
over  Gamma  nail with  lower  rate  of plant-related  complications  and  should  be  preferred  device  for
intertrochanteric  fractures.  However,  owing  to  the  low  quality  evidence  currently  available,  more  high-
quality RCTs  are  needed  to con
Level of evidence:  Level  II.
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. Introduction
With a growing aging population, the incidence of
ntertrochanteric fractures is rising [1]. It has been estimated
hat intertrochanteric fractures occur in more than 200,000 people
ach year in the United States, with reported mortality rates
anging from 15% to 30% [2].
There is a considerable debate regarding which is the optimal
mplant for ﬁxing intertrochanteric fractures. Options for treat-
ng intertrochanteric fractures include extramedullary ﬁxation and
ntramedullary ﬁxation. Dynamic hip screw (DHS), the most repre-
entative implant of extramedullary ﬁxation, has been considered
he gold standard for treatment of intertrochanteric fractures. How-
ver, DHS often fails to give good results in the unstable and reverse
blique fracture, which limits its clinical use [3,4]. Gamma  nail has
een widely used for many years because of its inspiring clinical
esults [5,6]. Long-term studies, however, revealed that Gamma
ail might cause higher intra-operative and late complications that
ften require revision surgery [7,8]. PFNA was designed to minimize
he risk of these implant-related complications, and preliminary
esults suggested that this goal might have been achieved [9,10].
ENA provides angular and rotational stability, which is especially
mportant in osteoporotic bone, and allows early mobilization and
eight bearing on the affected limb [11,12]. Biomechanical tests
ave shown its biomechanical superiority to sliding hip screw or
amma  nail [13].
Recently, a number of prospective randomized trials have been
erformed to compare the management of intertrochanteric frac-
ures using these three ﬁxation methods. However, these studies
ere limited in sample size and quality of methodology, and failed
o draw a deﬁnitive conclusion on which ﬁxation method is opti-
al  for intertrochanteric fractures in reducing complications and
mproving prognosis. Thus, to provide a strong support for clini-
al decision, we conducted an updated meta-analysis to evaluate
he efﬁcacy of three interventions in treatment of intertrochanteric
ractures through twelve evaluation criteria. The questions that
rive the current study were the following: which implant gives
he lower rates of blood loss, complications (peri-implant frac-
ure, ﬁxation failure, infection, thromboembolic), reoperation, and
ortality, as well as the minimal duration related to surgery (ﬂuo-
oscopic exposure, surgery and hospital stay).
. Methods
.1. Inclusion criteria
.1.1. Search strategy
The electronic databases of PubMed (1974–9/2013), Embase
1974–9/2013), and Web  of Science (1966–9/2013), Cochrane
ibrary (Issue 6, 2013), Embase (1974–9/2013), Google Scholar
1974–9/2013), Springer (1989–9/2013), and OVID (1992–9/2013)
ere searched using a sensitive methodological ﬁlter for etiol-
gy studies. The key words including “intertrochanteric fractures”,
proximal femoral nail antirotation”, “dynamic hip screw”, and
Gamma  nail” were used. Google Scholar and Medical matrix were
lso searched to investigate potentially relevant literature. In addi-
ion, the reference lists of included studies and all related review
rticles were checked for further trials, published or unpublished.
anguage and publication status date were not restricted, and gray
iteratures were also investigated, as well as ongoing trials..2. Data collection and analysis
.2.1. Selection of studies
The inclusion criteria are as follows:Surgery & Research 100 (2014) 859–866
• patients over 60 years old with stable or unstable peritrochanteric
fractures (peritrochanteric or intertrochanteric), excluding the
pathological fractures;
• interventions including, DHS Gamma  nail, or PFNA ﬁxation;
• prospective, randomized controlled trials.
Duplicates or multiple publications of the same study, case
reports, and animal studies were excluded from this review.
Twelve indicators assessed the outcomes:
• operative time;
• ﬂuoroscopy time;
• operative blood loss;
• length of hospital stays (days);
• wound infection or hematoma;
• pneumonia;
• thromboembolic complications;
• ﬁxation failure;
• operative fracture of femur;
• later fracture of femur;
• re-operation;
• mortality.
Two authors independently undertook the screening of studies.
An initial screening of titles and abstracts was performed to remove
those that were obviously outside the scope of the review. When
the title or abstract could not be rejected with certainty, the full
text article was  obtained for further evaluation.
2.2.2. Data extraction and management
Data were extracted for all studies that met the inclusion crite-
ria. For each study, two  review authors independently completed
data extraction forms that were tailored to the requirements of this
review. All disagreements were resolved by discussion between the
two review authors. If consensus could not be made, a third review
author would be asked to complete the data extraction form and
discuss the paper with the other two authors until the consensus
was reached. If any data were missing from the trial reports, the
review authors would attempt to obtain the data by contacting the
authors. Any disagreement was resolved by discussion.
2.2.3. Assessment of risk of bias in included studies
Two reviewers assessed each study according to the modiﬁed
Jadad Scale independently [14]. In this scale, the maximum quality
score is seven points. The points are given according to the follow-
ing rules: two points for appropriate methods of randomization,
two for appropriate methods of blinding, two  for appropriate meth-
ods of allocation concealment, and one for all enrolled patients
participate in the study except for those who quit with reason.
Low quality studies were rated score zero to three points and high
quality four to seven points.
2.2.4. Data synthesis
This study used the Review Manager 5.1 software for meta-
analysis (Copenhagen: The Nordic Cochrane Centre, the Cochrane
Collaboration). When there were dichotomous variables, risk ratios
(RR) were calculated for each study. When the data were contin-
uous and the standardized mean difference (SMD) or the mean
difference (MD) was used, 95% conﬁdence intervals were deter-
mined for all effect sizes. Heterogeneity was  analyzed using Chi2
tests before meta-analysis (P = 0.05). If there was no heterogene-
ity (P ≥ 0.05, I2 < 50%), a ﬁxed effect model was used, otherwise
(P < 0.05) a random effect model was  used. Sensitivity analysis was
carried out by removing relevant research to observe whether the
homogeneity and the results changed signiﬁcantly. If it did, this
was used to ﬁnd the reason of heterogeneity for further analysis.
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e then judged the results for stability and strength. If the het-
rogeneity was too large to analyze, the descriptive analysis was
resented.
. Results
.1. Description of studies
The literature search yielded 123 studies, including 52 dupli-
ates or duplicate publications which were eliminated at ﬁrst. 11
tudies clearly did not match our inclusion criteria by title and
bstract and were excluded then. No data was obtained from gray
iterature investigation as well from ongoing trials (we had no
nswer from the authors despite they were contacted). For the
emaining 60 papers, the full articles were retrieved and assessed
ccording to our inclusion criteria. 46 of these did not meet the
nclusion criteria. Therefore, 14 prospective randomized controlled
rials were included in this review. The list of studies excluded
nd reasons for exclusion are shown in Fig. 1. The assessment of
tudy quality was present in Table 1. The characteristics of included
tudies are shown in Table 2.
.2. Effects of interventions
.2.1. Operative time (minutes)
Three studies reported the comparison of operative time
etween PFNA group and DHS group. The heterogeneity test
howed a statistical heterogeneity among these studies (I2 = 99%,
 < 0.00001) and random-effects model was adopted. No statisticalreening process.
difference was found between PFNA group and DHS group in terms
of operative time (MD  –14, 95% CI –44.50 to 16.50; P = 0.37). Simi-
larly, pooled results showed that there was no statistical difference
whether between DHS group and Gamma  nails group (MD  0.16,
95% CI –0.24 to 0.57; P = 0.42) or between PFNA group and Gamma
nails group (MD  –4.50, 95% CI –5.23 to –3.77; P < 0.00001).
3.2.2. Fluoroscopy time
Comparison of ﬂuoroscopy time between PFNA group and DHS
group was available in two studies. Data pooled by a ﬁxed-effects
model conﬁrmed that ﬂuoroscopy time with PFNA was  greater than
with DHS (MD  2.11, 95% CI 1.78 to 2.43; P < 0.00001) (Fig. 1). Only
one study involved the comparison of ﬂuoroscopy time between
PFNA group and Gamma  nail group. Pooled result indicated that
ﬂuoroscopy time with PFNA was less than with Gamma nail (MD
–0.50, 95% CI –0.55 to –0.45; P < 0.00001). No data were eligible to
compare DHS with Gamma  nail in terms of ﬂuoroscopy time.
3.2.3. Operative blood loss
Four studies investigated the difference of operative blood loss
between PFNA group and DHS group. Data pooled by a ﬁxed-
effects model demonstrated that operative blood loss with PFNA
was less than with DHS (MD  –253.86, 95% CI –270.25 to –237.47;
P < 0.00001) (Fig. 2). Analogously, pooled results of one study indi-
cated that blood loss with PFNA was  less than with Gamma  nail (MD
–55.30, 95% CI –60.07 to –50.53; P < 0.00001). Expectedly, pooled
results of four studies revealed that operative blood loss with DHS
was greater than with Gamma  nail (MD  29.49, 95% CI 8.27 to 50.70;
P = 0.006) (Fig. 3).
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Table 1
Quality assessment according to the modiﬁed Jadad Scale.
Study [reference] Random sequence generation Allocation concealment Blinding Withdrawals or dropouts (%) Quality score
Zou et al. [15] Unclear Unclear Unclear 0 2
Adams et al. [16] Unclear Closed envelope Unclear 0.25 4
Butt  et al. [17] Even-numbered and odd-numbered Unclear Unclear 0 2
Bridle et al. [18] Unclear Unclear Unclear 34 2
Yaozeng et al. [19] Computer-generated Sealed envelope Unclear 31.6 5
O’Brien et al. [20] Unclear Blind-envelope Unclear 6.9 4
Garg  et al. [21] Random number Unclear Unclear 8.6 3
Leung et al. [22] Sequence of admission Unclear Unclear 17.7 3
Madsen et al. [23] Unclear Unclear Unclear 21.5 2
Verettas et al. [24] Unclear Unclear Unclear 1.7 2
Haynes et al. [25] Unclear Unclear Unclear 0 2
Kukla et al. [26] Unclear Sealed envelopes Unclear 3 4
Xu  et al. [27] Computer-generated Sealed envelopes Unclear 7.5 5
Radford et al. [28] Unclear Unclear Unclear 11 3
Table 2
Characteristics of included studies.
Study [reference] Age No. of fractures in each group Outcomes Target population
PFNA DHS Gamma  nail PFNA DHS Gamma nail
Zou et al. [15] 65 65 58 63 1–4,9–11 China
Adams  et al. [16] 80.7 81.2 197 203 1–2,4–7,10,12 UK
Butt  et al. [17] 78 79 48 47 5–10,12 UK
Bridle  et al. [18] 82.7 81.0 51 49 4–6,8–10,12 UK
Yaozeng et al. [19] 76.0 ± 1.2 75.4 ± 1.0 66 70 1–4,6,8,9–12 China
O’Brien  et al. [20] 77 83 49 53 1–2,4–12 Canada
Garg  et al. [21] 60.2 64.3 42 39 1,4,7,10,12 India
Leung  et al. [22] 78.27 80.86 113 113 2,4–9,11–12 Hong Kong
Madsen et al. [23] 78.9 ± 11.7 78.1 ± 10.3 85 50 4–6,8–12 Norway
Verettas et al. [24] 81.03 ± 6.3 79.22 ± 7.9 60 60 1–2,4,9–12 Greece
Haynes  et al. [25] 84 ± 8.3 83 ± 9.1 60 60 1–2,5–12 Austria
Kukla  et al. [26] 72–90 72–90 23 18 4,7,12 Netherlands
Xu  et al. [27] 78.5 ± 7.9 77.9 ± 7.8 51 55 1–6,8,10–12 China
Radford et al. [28] 78 83 100 100 4–7,9–10,12 UK
Outcomes: 1. Length of surgery; 2. Operative blood loss; 3. Fluoroscopy time; 4. Fixation failure; 5. Operative fracture of femur; 6. Later fracture of femur; 7. Reoperation; 8.
Pneumonia; 9. Thromboembolic complications; 10. Wound infection OR haematoma; 11. Length of hospital stay (days); 12. Mortality.
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.2.4. Length of hospital stay (days)
Only one study reported the comparison of length of hospi-
al stay between PFNA group and DHS group. Data pooled by a
xed-effects model indicated that there was no statistical differ-
nce between the two groups (MD  –0.40, 95% CI –1.03 to 0.23;
 = 0.21). Analogously, pooled results also showed that there was
o statistical difference between DHS group and Gamma nail group
MD  0.16, 95% CI –0.24 to 0.57; P = 0.42). However, we  found PFNA
igniﬁcantly shortened the length of hospital stay compared with
amma  nail (MD  –0.20, 95% CI –0.27 to –0.13; P < 0.00001).
Fig. 3. Forest plot diagram showing operativcopy time when using PFNA or DHS.
3.2.5. Wound infection or hematoma
Comparison of wound infection or hematoma between PFNA
group and DHS group were documented in two  studies. Data
pooled by a random-effects model showed no statistical difference
between the two groups (MD  0.26, 95% CI 0.01 to 4.90; P = 0.37).
Analogously, pooled results indicated that there was  no difference
whether between DHS group and Gamma nail group (MD 0.90, 95%
CI 0.55 to 1.48; P = 0.68) or between PFNA group and Gamma  nail
group (MD  1.07, 95% CI 0.36 to 3.15; P = 0.91) regarding the rate of
wound infection or hematoma.
e blood loss when using PFNA or DHS.
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.2.6. Pneumonia
Only one study provided the comparison of pneumonia rate
etween PFNA group and DHS group. Data pooled by a ﬁxed-effects
odel showed no statistical difference between the two groups
MD  0.41, 95% CI 0.08 to 2.20; P = 0.30). Similarly, pooled results
howed that there was no difference whether between DHS group
nd Gamma  nail group (MD  1.41, 95% CI 0.62 to 3.22; P = 0.42) or
etween PFNA group and Gamma  nail group (MD  1.35, 95% CI 0.35
o 5.27; P = 0.66) with respect to pneumonia rate.
.2.7. Thromboembolic complications
Eight studies reported the comparison of thromboembolic com-
lications between DHS group and Gamma  nail group. We  pooled
ata by a ﬁxed-effects model which demonstrated that there was
o statistical difference in thromboembolic complications between
he two groups (MD  0.73, 95% CI 0.50 to 1.07; P = 0.11). No data
ere eligible to compare PFNA with DHS or PFNA with Gamma  nail
oncerning the thromboembolic complications.
.2.8. Fixation failure
To compare the ﬁxation failure rate between PFNA group and
HS group, we conducted subgroup analysis which conﬁrmed that
xation failure rate with PFNA was lower than with DHS (MD  0.20,
5% CI 0.07 to 0.59; P = 0.004) (Fig. 4). However, pooled results
howed no statistical difference whether between DHS group and
amma  nail group (MD  0.87, 95% CI 0.55 to 1.37; P = 0.55) or
etween PFNA group and Gamma  nail group (MD  2.23, 95% CI 0.53
o 9.32; P = 0.27) with respect to ﬁxation failure rate.
.2.9. Operative fracture of femur
Only one study reported the comparison of operative femur frac-
ure rate between PFNA group and DHS group. Data pooled by a
xed-effects model indicated that there was no statistical differ-
nce between the two groups (MD  5.61, 95% CI 0.26 to 119.62;
 = 0.27). However, pooled results of six studies showed that oper-
tive femur fracture rate with DHS was lower than with Gamma nail
MD  0.31, 95% CI 0.11 to 0.89; P = 0.03) (Fig. 5). No data were eligible
o compare PFNA with Gamma  nail in operative femur fracture.
.2.10. Later fracture of femur
Only one study investigated the difference of later femur frac-
ure rate between PFNA group and DHS group. We  pooled data
y a ﬁxed-effects model, which showed no statistical difference
etween the two groups (MD  3.30, 95% CI 0.13 to 82.78; P = 0.47).
nalogously, pooled results indicated that there was no difference
etween PFNA group and Gamma  nail group (MD  3.29, 95% CI
.33 to 32.41; P = 0.31). However, pooled results of eight studies
howed that later femur fracture rate with DHS were lower than
ith Gamma  nail (MD  0.16, 95% CI 0.06 to 0.43; P = 0.0004) (Fig. 6).
.2.11. Reoperation
Only one study provided the comparison data of reoperation
ate between PFNA group and DHS group. Pooled data indicated
hat there was no difference between the two groups (MD  0.06,
5% CI 0.00 to 1.12; P = 0.06). However, pooled data of seven stud-
es (1144 patients) showed that reoperation rate with DHS was
ess than with Gamma  nail (MD  0.49, 95% CI 0.27 to 0.88; P = 0.02)
Fig. 7). No data were eligible to compare reoperation rates with
FNA versus Gamma  (Fig. 8).
.2.12. Mortality
Only one study reported the comparison of mortality rateetween PFNA group and DHS group. Data pooled by a ﬁxed effects-
odel showed no statistical difference between the two groups
MD  1.26, 95% CI 0.26 to 6.04; P = 0.77). Similarly, pooled results of
even studies conﬁrmed that there was no difference between DHSSurgery & Research 100 (2014) 859–866 863
and Gamma  nail on the mortality rate (MD  0.97, 95% CI 0.72 to 1.30;
P = 0.84). No data were eligible to compare PFNA with Gamma  nail
in mortality.
4. Discussion
The optimal management of intertrochanteric fractures is still
controversial. DHS and Gamma  nail were most commonly used
for ﬁxing intertrochanteric fractures in the last decade [29]. How-
ever, PFNA, the latest developed device, is considered as a perfect
device for intertrochanteric fracture with a lower incidence of
complications [9,10]. Previous randomized controlled trials and
meta-analyses failed to draw a unanimous conclusion. To facili-
tate a clinical decision, we conducted an updated meta-analysis
to determine the optimal treatment of intertrochanteric fractures.
Our meta-analysis suggests that PFNA can beneﬁt intertrochanteric
fractures with less blood loss and lower rate of ﬁxation failure in
comparison with DHS and Gamma  nail; while DHS has advantages
of lower rate of operative fracture of femur, later fracture of femur,
and reoperation in comparison with Gamma nail.
The following limitations of this meta-analysis should be
acknowledged. Firstly, despite a comprehensive search without any
restriction, not all related randomized trials are included mainly
because of publication bias or selection bias. Strict searches in the
library and included bibliographies were conducted to reduce these
biases. Secondly, many trials in our study included both stable
and unstable fractures, and we were unable to obtain adequate
information from the included studies to make any distinction in
outcome for unstable versus stable intertrochanteric fractures. This
may  cause an over- or under-estimation of the true results. There-
fore, we  will consider the potential for presenting a summary of the
evidence based on fracture type in our next meta-analysis. Thirdly,
many trials herein involve different generations of Gamma nails,
and the newer-generation implant is associated with decreased risk
of implant-related fractures, which may  affect the overall therapeu-
tic effect of Gamma  nail. Hence, we  will conduct a subgroup analysis
in terms of different generations of Gamma  nails in our next meta-
analysis. Lastly, we failed to assess the heterogeneity of populations
regarding age level of autonomy and gender between studies. To
compensate for this deﬁciency, we  will assess the heterogeneity of
these two  factors in our next meta-analysis.
In the current study, we  found no signiﬁcant difference in sev-
eral parameters (length of surgery, pneumonia, thromboembolic
complications, and wound infection or hematoma) among PFNA,
DHS, and Gamma  nail. Our ﬁndings revealed that PFNA signiﬁcantly
reduced the length of hospital stay compared with Gamma nail,
which implied that PFNA is superior to Gamma  nail in terms of
postoperative recovery.
In regard to blood loss, pooled results showed that fracture ﬁxa-
tion with DHS led to more blood loss than with PFNA or Gamma
nail. And this ﬁnding was  supported by other meta-analyses
[30,31]. Shen et al. [30] compared PFNA with DHS for treatment
of intertrochanteric fractures, and they concluded that PFNA could
beneﬁt intertrochanteric fractures patients with less blood loss and
fewer complications. This may  be because DHS placement requires
a relatively large exposure and signiﬁcant soft tissue stripping,
which cause serious bleeding [32]. However, Giraud et al. [33]
reported a different ﬁnding that using the DHS was associated with
less blood loss and at a lower cost in comparison with proximal
femoral nail. Noteworthy, in order to avoid the surgical trauma of
DHS, the Gotfried percutaneous compression plate (PCCP, Orthoﬁx
McKinney, Texas, USA) was  developed for ﬁxing intertrochanteric
fractures with a minimally invasive method [34]. This device is
mainly indicated for intertrochanteric fractures with intact lateral
walls (AO type 31.A1, 31.A2, B2.1). And its theoretical advantages
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Fig. 4. Forest plot diagram showing operative blood loss when using Gamma nail or DHS.
Fig. 5. Forest plot diagram showing the ﬁxation failure rate when using PFNA or DHS.
Fig. 6. Forest plot diagram showing the operative femur fracture odds ratios when using DHS or Gamma nail.
Fig. 7. Forest plot diagram showing rates of later femur fracture when using DHS or Gamma nail.
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re the provision of rotational stability, by using two screws in the
emoral neck, and a reduction in the lateral cortical damage [35].
a  et al. [36] performed a meta-analysis comparing PCCP with
HS for treatment of intertrochanteric fractures, and reported that
CCP allowed signiﬁcantly shorter operative time, reduced blood
nd transfusion, as well as diminished incidence of cardiovascular
vents.
As many studies indicate, although an attractive biomechan-
cal concept, Gamma  nail has been associated with a signiﬁcantly
ncreased risk of intra-operative and later fracture around or below
he implant [7,8,16]. In our ﬁndings, Gamma  nail indeed resulted
n a higher risk of intra-operative and later fracture compared with
HS. This is also consistent with the results of many relevant sys-
ematic reviews [8,14,37]. These complications were attributed
argely to the original design features of Gamma nail, leading
o the redesign of newer-generation implants. Inspiringly, with
ewer designs and an improved understanding of the Gamma nail
echnique, risks of femoral shaft fractures signiﬁcantly decreased
38,39]. In addition, another enhancer of Gamma nail was  Bocchi,
ertone, Caniggia, Maniscalco (BCMTM) (LimaTM, Villanova, Italy)
ail. It was designed to combine the advantages of the nail and
ts intrinsic stability with those of the screw-plate device (cephalic
crew positioning, intra-operative impaction of up to 10 mm)  with-
ut having the drawbacks of the Gamma  nail (smaller nail diameter,
pportunity to change with a plate) and of the screw-plate (post-
perative impaction within the fracture site). In 1999, a series of
6 intertrochanteric fracture patients from Siena (Italy) had been
eported beneﬁting from the insertion of this innovative ﬁxation
evice [40]. Foulongne et al. [41] performed a case-control study
n BCMTM nail versus DHS to ﬁx pertrochanteric fractures. They
ound that BCMTM nail was associated with lower incidence of sec-
ndary displacement, higher healing rate, and better functional
ecovery. In addition, no intraoperative implant-related fractures
ere observed in the BCMTM subgroup of patients.
There were no signiﬁcant differences in intra-operative and later
emoral shaft fracture between PFNA and DHS, and this impor-
ant ﬁnding was supported by another meta-analysis [31]. PFNA
as designed to minimize the risk of these implant-related com-
lications, and preliminary results suggested that this goal might
ave been achieved [9,10]. The inserted PFNA blade achieves an
xcellent ﬁt via bone compaction and requires less bone removal
han a screw does, which provides angular and rotational stabil-
ty and is very beneﬁcial for unstable intertrochanteric fractures or
atients with osteoporosis [11,42]. And these advantages ensure
he patient’s early mobilization and weight bearing on the affected
imb [11,12].
No signiﬁcant difference was found in ﬁxation failure (cutting-
ut or non-union) between Gamma  nail and PFNA or DHS. However,
imilar to the previous study, a signiﬁcant lower risk of ﬁxation fail-
re was found in PFNA group in comparison with DHS [31]. Relative
o DHS, PFNA is an intramedullary device with a helical blade rather
[n rates when using DHS or Gamma nail.
than with a screw; this allows a better purchase in the femoral head
to limit cut-outs due to varus deviation and rotation. In terms of
reoperation, present results show that PFNA had no evidence of
superiority to DHS. However, we  found DHS  was associated with a
lower risk of reoperation than Gamma  nail, which was contrary to
the previous meta-analysis [43,44].
In conclusion, PFNA should be a priority choice for treatment of
intertrochanteric fractures with minimal rate of ﬁxation failure, less
blood loss and shorter length of hospital stay. While DHS has dis-
tinct advantages over Gamma  nail with lower rate of plant-related
complications and should be preferred device for intertrochanteric
fractures. However, owing to the low quality evidence currently
available, more high-quality RCTs are needed to conﬁrm the ﬁnd-
ings from this meta-analysis, and the effects of long-term period
also need further study to improve clinical decision-making.
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